Table 1.

Subjects’ demographic data by initial treatment.

VariableFebuxostat 80 mg, N = 649Febuxostat 120 mg, N = 292Allopurinol, N = 145
Serum urate (mg/dl), n (%)
  < 9.0183 (28.2)97 (33.2)36 (24.8)
  9.0 to < 10.0219 (33.7)90 (30.8)54 (37.2)
  ≥ 10.0247 (38.1)105 (36.0)55 (37.9)
  Mean ± SD9.83 ± 1.2539.74 ± 1.2819.82 ± 1.157
Renal function, n (%)
  Normal636 (98.0)286 (97.9)144 (99.3)
  Impaired*13 (2.0)6 (2.1)1 (0.7)
Medical history, n (%)
  Cardiovascular disease71 (10.9)33 (11.3)14 (9.7)
  Congestive heart failure11 (1.7)8 (2.7)0
  Diabetes46 (7.1)15 (5.1)12 (8.3)
  Hypercholesterolemia48 (7.4)16 (5.5)9 (6.2)
  Hyperlipidemia229 (35.3)89 (30.5)47 (32.4)
  Hypertension295 (45.5)115 (39.4)73 (50.3)
Alcohol use, n (%)
  Drinker433 (66.74)197 (67.5)105 (72.4)
  Non-/Ex-drinker216 (33.3)95 (32.5)40 (27.6)
Race, n (%)
  Asian19 (2.9)4 (1.4)5 (3.4)
  Black or African American51 (7.9)30 (10.3)15 (10.3)
  White519 (80.0)233 (79.8)110 (75.9)
  Hispanic or Latino40 (6.2)15 (5.1)11 (7.6)
  Other20 (3.1)10 (3.4)4 (2.8)
Age, yrs, n (%)
  < 45192 (29.6)86 (29.5)45 (31.0)
  45 to 65373 (57.5)178 (61.0)89 (61.4)
  > 6584 (12.9)28 (9.6)11 (7.6)
  Mean ± SD51.4 ± 11.9550.9 ± 11.5751.0 ± 11.30
  Range24–8424–8429–83
Weight, lb
  Mean ± SD223.3 ± 43.01230.3 ± 47.87234.7 ± 49.69
  Range123–390135–399136–468
BMI, kg/m2, n (%)
  < 18.5000
  18.5 to < 2540 (6.2)10 (3.4)6 (4.1)
  25 to < 30215 (33.1)92 (31.5)42 (29.0)
  ≥ 30394 (60.7)189 (64.7)97 (66.9)
  Missing01 (0.3)0
  Mean ± SD32.3 ± 5.7833.2 ± 6.1733.8 ± 6.79
  Range21–6122–5921–65
Height, in
  Mean ± SD69.7 ± 3.2469.8 ± 3.1869.9 ± 3.32
  Range59–8061–7859–79
  • * Defined as serum creatinine > 1.5 mg/dl.

  • 1–14 drinks/wk.